Xencor

XNCR NASDAQ
44.96
-0.63
-1.38%
Opening 10:58 07/19 EDT
Open
45.42
Prev Close
45.59
High
45.86
Low
44.08
Volume
41.35K
Avg Vol (3M)
487.50K
52 Week High
48.38
52 Week Low
27.75
% Turnover
0.07%
Market Cap
2.53B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Xencor XNCR stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
MORE >

Recently

Name
Price
%Change